| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parathyroidectomy | 56 | 2023 | 203 | 12.830 |
Why?
|
| Hyperparathyroidism, Primary | 38 | 2023 | 135 | 12.550 |
Why?
|
| Parathyroid Neoplasms | 40 | 2023 | 185 | 10.770 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 27 | 2024 | 141 | 8.960 |
Why?
|
| Thyroidectomy | 40 | 2020 | 486 | 8.760 |
Why?
|
| Adrenal Gland Neoplasms | 31 | 2024 | 489 | 6.430 |
Why?
|
| Adrenalectomy | 23 | 2022 | 188 | 5.520 |
Why?
|
| Pheochromocytoma | 22 | 2023 | 281 | 5.020 |
Why?
|
| Thyroid Neoplasms | 47 | 2023 | 1866 | 4.950 |
Why?
|
| Adrenocortical Carcinoma | 18 | 2024 | 172 | 4.460 |
Why?
|
| Parathyroid Hormone | 25 | 2023 | 194 | 4.430 |
Why?
|
| Hyperparathyroidism | 19 | 2021 | 93 | 4.410 |
Why?
|
| Parathyroid Glands | 26 | 2022 | 127 | 3.990 |
Why?
|
| Adrenal Cortex Neoplasms | 18 | 2024 | 223 | 3.940 |
Why?
|
| Neuroendocrine Tumors | 13 | 2023 | 634 | 2.780 |
Why?
|
| Robotics | 9 | 2013 | 359 | 2.750 |
Why?
|
| Minimally Invasive Surgical Procedures | 18 | 2021 | 500 | 2.640 |
Why?
|
| Endocrine Surgical Procedures | 6 | 2016 | 14 | 2.540 |
Why?
|
| Paraganglioma | 12 | 2023 | 170 | 2.490 |
Why?
|
| Thyroid Diseases | 9 | 2020 | 85 | 2.470 |
Why?
|
| Hypercalcemia | 7 | 2022 | 137 | 2.460 |
Why?
|
| General Surgery | 10 | 2017 | 326 | 2.400 |
Why?
|
| Adenoma | 17 | 2022 | 716 | 2.150 |
Why?
|
| Hypoparathyroidism | 5 | 2022 | 49 | 1.940 |
Why?
|
| Carcinoma, Papillary | 10 | 2020 | 584 | 1.700 |
Why?
|
| Humans | 268 | 2024 | 261506 | 1.660 |
Why?
|
| Thyroid Nodule | 6 | 2018 | 92 | 1.560 |
Why?
|
| Retrospective Studies | 98 | 2024 | 37905 | 1.490 |
Why?
|
| Middle Aged | 143 | 2024 | 86204 | 1.470 |
Why?
|
| Laparoscopy | 13 | 2018 | 1225 | 1.380 |
Why?
|
| Postoperative Complications | 18 | 2022 | 5542 | 1.370 |
Why?
|
| Adult | 128 | 2024 | 77950 | 1.330 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 8 | 2018 | 115 | 1.310 |
Why?
|
| Carcinoma | 12 | 2019 | 2578 | 1.290 |
Why?
|
| Male | 150 | 2023 | 123000 | 1.280 |
Why?
|
| Four-Dimensional Computed Tomography | 6 | 2019 | 226 | 1.240 |
Why?
|
| Retroperitoneal Space | 8 | 2018 | 145 | 1.220 |
Why?
|
| Female | 158 | 2023 | 141928 | 1.210 |
Why?
|
| Aged | 113 | 2021 | 70117 | 1.210 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10035 | 1.150 |
Why?
|
| Pancreatic Neoplasms | 14 | 2023 | 5061 | 1.130 |
Why?
|
| Societies, Medical | 6 | 2021 | 1335 | 1.110 |
Why?
|
| Preoperative Care | 17 | 2019 | 1529 | 1.060 |
Why?
|
| Multiple Endocrine Neoplasia | 2 | 2020 | 57 | 1.060 |
Why?
|
| Calcium | 15 | 2023 | 1537 | 1.040 |
Why?
|
| Succinate Dehydrogenase | 4 | 2023 | 43 | 1.040 |
Why?
|
| Health Care Costs | 2 | 2020 | 674 | 1.020 |
Why?
|
| Vitamin D Deficiency | 4 | 2012 | 115 | 1.010 |
Why?
|
| Hematoma | 2 | 2016 | 160 | 1.010 |
Why?
|
| Endocrine Gland Neoplasms | 3 | 2017 | 42 | 1.000 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2017 | 259 | 1.000 |
Why?
|
| Neck | 7 | 2021 | 383 | 0.990 |
Why?
|
| Awards and Prizes | 2 | 2016 | 98 | 0.990 |
Why?
|
| Surgeons | 2 | 2022 | 519 | 0.960 |
Why?
|
| Proto-Oncogene Proteins c-ret | 10 | 2018 | 370 | 0.930 |
Why?
|
| Thyroid Gland | 7 | 2019 | 355 | 0.930 |
Why?
|
| Follow-Up Studies | 40 | 2021 | 14889 | 0.930 |
Why?
|
| Cushing Syndrome | 2 | 2022 | 70 | 0.920 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2020 | 7551 | 0.900 |
Why?
|
| Adenocarcinoma, Follicular | 5 | 2019 | 132 | 0.900 |
Why?
|
| Neoplasm Staging | 20 | 2023 | 13658 | 0.890 |
Why?
|
| Endocrine System | 1 | 2022 | 36 | 0.880 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 10331 | 0.870 |
Why?
|
| Hospital Costs | 3 | 2024 | 228 | 0.860 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2022 | 24 | 0.850 |
Why?
|
| Securin | 2 | 2018 | 11 | 0.840 |
Why?
|
| Hospitals, High-Volume | 2 | 2020 | 77 | 0.830 |
Why?
|
| Genetic Testing | 9 | 2021 | 1589 | 0.820 |
Why?
|
| Technetium Tc 99m Sestamibi | 13 | 2019 | 121 | 0.810 |
Why?
|
| Adrenal Gland Diseases | 2 | 2013 | 72 | 0.800 |
Why?
|
| Interprofessional Relations | 2 | 2017 | 213 | 0.800 |
Why?
|
| Young Adult | 43 | 2021 | 21445 | 0.800 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 224 | 0.780 |
Why?
|
| Adolescent | 51 | 2021 | 31252 | 0.780 |
Why?
|
| Hyperaldosteronism | 2 | 2019 | 19 | 0.780 |
Why?
|
| Pituitary Neoplasms | 2 | 2020 | 203 | 0.780 |
Why?
|
| Carcinoma, Neuroendocrine | 8 | 2023 | 716 | 0.740 |
Why?
|
| Economics, Behavioral | 1 | 2020 | 12 | 0.730 |
Why?
|
| Aged, 80 and over | 50 | 2020 | 29902 | 0.720 |
Why?
|
| Social Responsibility | 1 | 2020 | 92 | 0.710 |
Why?
|
| Treatment Outcome | 45 | 2021 | 32848 | 0.690 |
Why?
|
| Surgical Oncology | 1 | 2021 | 190 | 0.690 |
Why?
|
| Hyperglycemia | 1 | 2022 | 333 | 0.690 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2023 | 607 | 0.670 |
Why?
|
| Remote Consultation | 2 | 2016 | 37 | 0.670 |
Why?
|
| Endoscopy | 3 | 2013 | 479 | 0.670 |
Why?
|
| Carcinoma, Medullary | 7 | 2017 | 248 | 0.660 |
Why?
|
| Operating Rooms | 1 | 2020 | 122 | 0.660 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 306 | 0.660 |
Why?
|
| Radiopharmaceuticals | 15 | 2019 | 1301 | 0.660 |
Why?
|
| Sleep Wake Disorders | 5 | 2013 | 348 | 0.650 |
Why?
|
| Vitamin D | 4 | 2009 | 261 | 0.640 |
Why?
|
| Prognosis | 27 | 2023 | 21713 | 0.640 |
Why?
|
| Hypoaldosteronism | 1 | 2017 | 3 | 0.620 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2023 | 2488 | 0.620 |
Why?
|
| Physician Executives | 1 | 2017 | 40 | 0.600 |
Why?
|
| United States | 21 | 2021 | 15433 | 0.600 |
Why?
|
| Aldosterone | 1 | 2017 | 72 | 0.600 |
Why?
|
| Adrenal Glands | 3 | 2018 | 122 | 0.590 |
Why?
|
| Protective Factors | 1 | 2017 | 106 | 0.590 |
Why?
|
| Reoperation | 10 | 2016 | 1382 | 0.590 |
Why?
|
| Clinical Competence | 3 | 2016 | 1270 | 0.580 |
Why?
|
| Achievement | 1 | 2016 | 41 | 0.580 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2018 | 305 | 0.570 |
Why?
|
| Parathyroid Diseases | 3 | 2012 | 17 | 0.560 |
Why?
|
| Cognition Disorders | 5 | 2013 | 786 | 0.560 |
Why?
|
| Bone Remodeling | 1 | 2016 | 104 | 0.560 |
Why?
|
| Thyroid Hormones | 2 | 2013 | 111 | 0.550 |
Why?
|
| Thymus Neoplasms | 3 | 2017 | 400 | 0.550 |
Why?
|
| Survival Rate | 18 | 2019 | 12221 | 0.540 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 280 | 0.530 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2016 | 551 | 0.530 |
Why?
|
| Axilla | 4 | 2012 | 902 | 0.520 |
Why?
|
| Germ-Line Mutation | 9 | 2023 | 1046 | 0.510 |
Why?
|
| Mentoring | 1 | 2016 | 87 | 0.500 |
Why?
|
| Video Recording | 1 | 2016 | 267 | 0.500 |
Why?
|
| Hyperthyroidism | 3 | 2004 | 52 | 0.500 |
Why?
|
| Hospital Charges | 1 | 2014 | 75 | 0.500 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2018 | 115 | 0.490 |
Why?
|
| Operative Time | 5 | 2020 | 217 | 0.490 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 481 | 0.480 |
Why?
|
| Thyroiditis | 1 | 2013 | 18 | 0.480 |
Why?
|
| Cost Savings | 1 | 2014 | 123 | 0.480 |
Why?
|
| Cryopreservation | 2 | 2008 | 175 | 0.480 |
Why?
|
| Endocrinology | 4 | 2020 | 139 | 0.470 |
Why?
|
| Interdisciplinary Communication | 3 | 2014 | 280 | 0.470 |
Why?
|
| Bone Density | 3 | 2023 | 476 | 0.470 |
Why?
|
| Child | 34 | 2023 | 29154 | 0.460 |
Why?
|
| Survival Analysis | 14 | 2018 | 9180 | 0.460 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 1162 | 0.460 |
Why?
|
| Radiation Protection | 1 | 2014 | 205 | 0.450 |
Why?
|
| Cell Nucleus | 1 | 2018 | 1620 | 0.450 |
Why?
|
| Estrogens | 1 | 2017 | 751 | 0.440 |
Why?
|
| Neck Dissection | 4 | 2020 | 290 | 0.440 |
Why?
|
| Intraoperative Care | 1 | 2014 | 259 | 0.430 |
Why?
|
| Biopsy, Needle | 9 | 2014 | 1363 | 0.420 |
Why?
|
| Ultrasonography | 9 | 2019 | 1863 | 0.420 |
Why?
|
| Osteocalcin | 1 | 2012 | 87 | 0.420 |
Why?
|
| Education, Medical | 2 | 2015 | 331 | 0.420 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 552 | 0.420 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 231 | 0.410 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.410 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2012 | 255 | 0.410 |
Why?
|
| Child, Preschool | 16 | 2021 | 16273 | 0.410 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2014 | 221 | 0.400 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 205 | 0.400 |
Why?
|
| Hypocalcemia | 1 | 2011 | 59 | 0.400 |
Why?
|
| Perioperative Care | 2 | 2016 | 451 | 0.400 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1022 | 0.400 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 4744 | 0.400 |
Why?
|
| Education, Distance | 1 | 2012 | 93 | 0.390 |
Why?
|
| Risk Assessment | 14 | 2021 | 6869 | 0.390 |
Why?
|
| Biopsy, Fine-Needle | 7 | 2019 | 690 | 0.390 |
Why?
|
| Risk | 2 | 2014 | 1972 | 0.390 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 622 | 0.390 |
Why?
|
| Prospective Studies | 15 | 2020 | 12873 | 0.380 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 671 | 0.380 |
Why?
|
| Monitoring, Intraoperative | 5 | 2022 | 264 | 0.370 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 82 | 0.370 |
Why?
|
| Incidental Findings | 3 | 2018 | 272 | 0.370 |
Why?
|
| Mentors | 1 | 2012 | 203 | 0.370 |
Why?
|
| Risk Factors | 12 | 2021 | 17523 | 0.370 |
Why?
|
| Laryngeal Nerves | 1 | 2009 | 7 | 0.370 |
Why?
|
| Models, Educational | 1 | 2010 | 95 | 0.360 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1014 | 0.360 |
Why?
|
| Lymphatic Metastasis | 9 | 2019 | 4844 | 0.360 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 1399 | 0.350 |
Why?
|
| Sensitivity and Specificity | 13 | 2019 | 4971 | 0.350 |
Why?
|
| Duodenal Neoplasms | 3 | 2021 | 138 | 0.350 |
Why?
|
| Pancreatectomy | 3 | 2024 | 652 | 0.350 |
Why?
|
| Age Factors | 10 | 2020 | 5377 | 0.350 |
Why?
|
| Lithium Carbonate | 1 | 2009 | 21 | 0.340 |
Why?
|
| Antimanic Agents | 1 | 2009 | 39 | 0.340 |
Why?
|
| Lymph Nodes | 6 | 2017 | 2967 | 0.330 |
Why?
|
| Tissue Survival | 1 | 2008 | 15 | 0.330 |
Why?
|
| Physicians, Women | 2 | 2017 | 105 | 0.330 |
Why?
|
| Length of Stay | 4 | 2020 | 1900 | 0.320 |
Why?
|
| Patient Safety | 1 | 2014 | 649 | 0.320 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 112 | 0.320 |
Why?
|
| Surveys and Questionnaires | 5 | 2018 | 5687 | 0.320 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2022 | 156 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2019 | 53 | 0.320 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 108 | 0.310 |
Why?
|
| Vitamins | 1 | 2008 | 157 | 0.310 |
Why?
|
| Cohort Studies | 10 | 2017 | 9244 | 0.310 |
Why?
|
| Algorithms | 3 | 2020 | 3890 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 9 | 2023 | 2403 | 0.310 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 2864 | 0.310 |
Why?
|
| Time Factors | 12 | 2024 | 12926 | 0.300 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2576 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 383 | 0.290 |
Why?
|
| Predictive Value of Tests | 9 | 2017 | 4892 | 0.290 |
Why?
|
| Telemedicine | 1 | 2012 | 471 | 0.280 |
Why?
|
| Postoperative Period | 3 | 2017 | 665 | 0.280 |
Why?
|
| History, 20th Century | 3 | 2016 | 574 | 0.280 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 332 | 0.280 |
Why?
|
| Parents | 1 | 2012 | 998 | 0.270 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 447 | 0.270 |
Why?
|
| Pneumothorax | 1 | 2007 | 153 | 0.270 |
Why?
|
| Internship and Residency | 1 | 2016 | 1375 | 0.270 |
Why?
|
| Transplantation, Autologous | 3 | 2021 | 1914 | 0.260 |
Why?
|
| Physician's Role | 2 | 2018 | 238 | 0.260 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 429 | 0.260 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 1226 | 0.260 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 376 | 0.260 |
Why?
|
| Hydrocortisone | 2 | 2022 | 388 | 0.260 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 502 | 0.250 |
Why?
|
| Immunotherapy | 1 | 2018 | 3341 | 0.250 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 48 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6207 | 0.250 |
Why?
|
| Gastrins | 2 | 2016 | 55 | 0.240 |
Why?
|
| Databases, Factual | 5 | 2015 | 2218 | 0.240 |
Why?
|
| Neoplasm Metastasis | 10 | 2021 | 5112 | 0.240 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 1085 | 0.240 |
Why?
|
| Gastrinoma | 2 | 2011 | 25 | 0.240 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 4557 | 0.240 |
Why?
|
| Regression Analysis | 4 | 2013 | 1546 | 0.240 |
Why?
|
| Multidetector Computed Tomography | 3 | 2022 | 150 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 5539 | 0.230 |
Why?
|
| Suture Techniques | 1 | 2006 | 319 | 0.230 |
Why?
|
| Mutation | 12 | 2023 | 15179 | 0.230 |
Why?
|
| Massage | 1 | 2003 | 15 | 0.230 |
Why?
|
| Aging | 1 | 2012 | 1582 | 0.230 |
Why?
|
| Thyrotropin | 2 | 2013 | 119 | 0.230 |
Why?
|
| Cosyntropin | 1 | 2022 | 6 | 0.220 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 158 | 0.220 |
Why?
|
| Critical Pathways | 1 | 2024 | 149 | 0.220 |
Why?
|
| Mitotane | 3 | 2022 | 39 | 0.220 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 229 | 0.220 |
Why?
|
| Analysis of Variance | 3 | 2014 | 2307 | 0.220 |
Why?
|
| Brain Diseases | 1 | 2006 | 403 | 0.210 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2010 | 67 | 0.210 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 140 | 0.210 |
Why?
|
| Radiology | 1 | 2007 | 434 | 0.210 |
Why?
|
| Neuropsychological Tests | 5 | 2009 | 1178 | 0.200 |
Why?
|
| Polyamines | 1 | 2021 | 75 | 0.200 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 5767 | 0.200 |
Why?
|
| Chromogranin A | 3 | 2016 | 65 | 0.200 |
Why?
|
| Biomarkers | 4 | 2017 | 5047 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2021 | 33 | 0.200 |
Why?
|
| Melanoma | 1 | 2018 | 5317 | 0.200 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 37 | 0.200 |
Why?
|
| Syndrome | 2 | 2023 | 1351 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 945 | 0.190 |
Why?
|
| Disease-Free Survival | 9 | 2016 | 10001 | 0.190 |
Why?
|
| Quality of Life | 6 | 2022 | 4532 | 0.190 |
Why?
|
| Postoperative Care | 2 | 2016 | 739 | 0.190 |
Why?
|
| Siblings | 1 | 2022 | 285 | 0.190 |
Why?
|
| Medical History Taking | 1 | 2021 | 173 | 0.190 |
Why?
|
| Genotype | 6 | 2020 | 4109 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2013 | 224 | 0.190 |
Why?
|
| Contrast Media | 5 | 2020 | 1472 | 0.190 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 4320 | 0.190 |
Why?
|
| Sex Factors | 4 | 2016 | 2139 | 0.180 |
Why?
|
| History, 19th Century | 2 | 2015 | 154 | 0.180 |
Why?
|
| Interpersonal Relations | 1 | 2002 | 290 | 0.180 |
Why?
|
| Mastectomy | 2 | 2006 | 1534 | 0.180 |
Why?
|
| Propofol | 1 | 2000 | 80 | 0.180 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.180 |
Why?
|
| Infant | 5 | 2020 | 13310 | 0.180 |
Why?
|
| Radiologists | 1 | 2021 | 163 | 0.180 |
Why?
|
| Incidence | 5 | 2023 | 5673 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2014 | 1391 | 0.170 |
Why?
|
| Acidosis | 1 | 2000 | 116 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2004 | 1415 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 211 | 0.170 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 166 | 0.170 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4298 | 0.170 |
Why?
|
| Pathology, Clinical | 1 | 2020 | 152 | 0.170 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 12 | 0.170 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2018 | 24 | 0.170 |
Why?
|
| Gardner Syndrome | 1 | 1998 | 7 | 0.170 |
Why?
|
| Pain, Postoperative | 2 | 2016 | 610 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2022 | 629 | 0.170 |
Why?
|
| Pilot Projects | 6 | 2014 | 2803 | 0.160 |
Why?
|
| Specialization | 1 | 1999 | 130 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7702 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2006 | 862 | 0.160 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 134 | 0.160 |
Why?
|
| Osteolysis | 1 | 2018 | 80 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 38 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2020 | 289 | 0.160 |
Why?
|
| CD8 Antigens | 1 | 2018 | 170 | 0.160 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 311 | 0.160 |
Why?
|
| Radionuclide Imaging | 6 | 2009 | 660 | 0.160 |
Why?
|
| Fatigue | 2 | 2016 | 1239 | 0.160 |
Why?
|
| Adrenocortical Adenoma | 1 | 2017 | 22 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 666 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 4314 | 0.160 |
Why?
|
| Recurrence | 4 | 2021 | 4758 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2018 | 73 | 0.150 |
Why?
|
| Medicine | 1 | 1999 | 137 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8223 | 0.150 |
Why?
|
| Narration | 1 | 2017 | 42 | 0.150 |
Why?
|
| CD3 Complex | 1 | 2018 | 314 | 0.150 |
Why?
|
| Intraoperative Period | 3 | 2006 | 246 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2022 | 899 | 0.150 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 980 | 0.150 |
Why?
|
| Nomograms | 1 | 2019 | 313 | 0.150 |
Why?
|
| Terminology as Topic | 2 | 2010 | 414 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2022 | 840 | 0.150 |
Why?
|
| Genes, p53 | 2 | 2014 | 1090 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2004 | 388 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2016 | 700 | 0.150 |
Why?
|
| Breast Neoplasms | 7 | 2008 | 15694 | 0.150 |
Why?
|
| Blood Pressure | 3 | 2019 | 1467 | 0.150 |
Why?
|
| Polymorphism, Genetic | 3 | 2008 | 1450 | 0.150 |
Why?
|
| Pancreatic Polypeptide | 1 | 2016 | 17 | 0.140 |
Why?
|
| Cognition | 2 | 2009 | 968 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 2 | 2014 | 231 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 473 | 0.140 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2010 | 31 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.140 |
Why?
|
| Preoperative Period | 2 | 2020 | 344 | 0.140 |
Why?
|
| False Positive Reactions | 3 | 2014 | 355 | 0.140 |
Why?
|
| Glucagon | 1 | 2016 | 196 | 0.140 |
Why?
|
| Kidney Calculi | 1 | 2016 | 40 | 0.140 |
Why?
|
| Splenic Vein | 1 | 2015 | 17 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3981 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 395 | 0.140 |
Why?
|
| Learning Curve | 1 | 2016 | 68 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 239 | 0.140 |
Why?
|
| Splenic Artery | 1 | 2015 | 50 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 795 | 0.130 |
Why?
|
| Positron-Emission Tomography | 4 | 2018 | 2173 | 0.130 |
Why?
|
| Hypertension | 2 | 2019 | 1503 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2020 | 548 | 0.130 |
Why?
|
| Dexmedetomidine | 1 | 2016 | 85 | 0.130 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 66 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 1648 | 0.130 |
Why?
|
| Disease Progression | 6 | 2023 | 6682 | 0.130 |
Why?
|
| Fentanyl | 1 | 2016 | 148 | 0.130 |
Why?
|
| Glucose Transport Proteins, Facilitative | 2 | 2005 | 27 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 602 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2016 | 126 | 0.130 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 2283 | 0.130 |
Why?
|
| North Carolina | 2 | 2006 | 125 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 441 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Myosin Heavy Chains | 1 | 2014 | 128 | 0.120 |
Why?
|
| Conversion to Open Surgery | 1 | 2014 | 10 | 0.120 |
Why?
|
| Specialties, Surgical | 1 | 2016 | 137 | 0.120 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2014 | 27 | 0.120 |
Why?
|
| Chronobiology Disorders | 1 | 2003 | 10 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 403 | 0.120 |
Why?
|
| Preimplantation Diagnosis | 1 | 2014 | 47 | 0.120 |
Why?
|
| Medical Records | 2 | 2006 | 415 | 0.120 |
Why?
|
| Registries | 2 | 2023 | 2170 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 2 | 2018 | 53 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2019 | 2054 | 0.120 |
Why?
|
| Republic of Korea | 1 | 2013 | 70 | 0.120 |
Why?
|
| Tomography, Emission-Computed | 3 | 2003 | 310 | 0.120 |
Why?
|
| Thymectomy | 1 | 2013 | 79 | 0.120 |
Why?
|
| Spleen | 1 | 2015 | 676 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 1165 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2016 | 295 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2014 | 233 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 550 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2018 | 1385 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 992 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 7548 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2010 | 2292 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 100 | 0.110 |
Why?
|
| Videoconferencing | 1 | 2013 | 56 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2007 | 829 | 0.110 |
Why?
|
| Survivors | 1 | 2018 | 1031 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 803 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 1248 | 0.110 |
Why?
|
| Diaphragm | 1 | 2014 | 181 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 221 | 0.110 |
Why?
|
| Thyroxine | 1 | 2012 | 116 | 0.110 |
Why?
|
| Consensus | 1 | 2016 | 978 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1148 | 0.110 |
Why?
|
| Hyperplasia | 3 | 2006 | 557 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2023 | 2231 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Macrophages | 1 | 2018 | 1304 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2011 | 31 | 0.100 |
Why?
|
| Calcitonin | 1 | 2012 | 186 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 2359 | 0.100 |
Why?
|
| Decision Trees | 1 | 2012 | 178 | 0.100 |
Why?
|
| Pancreatitis | 1 | 1994 | 267 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2012 | 116 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 876 | 0.100 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2011 | 19 | 0.100 |
Why?
|
| Subtraction Technique | 2 | 2009 | 141 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.100 |
Why?
|
| Hypothyroidism | 1 | 2012 | 204 | 0.100 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 75 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 8865 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 275 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2010 | 59 | 0.090 |
Why?
|
| Safety Management | 1 | 2011 | 132 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 3230 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 1209 | 0.090 |
Why?
|
| Preceptorship | 1 | 2010 | 35 | 0.090 |
Why?
|
| Electromyography | 1 | 2011 | 226 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 469 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1959 | 0.090 |
Why?
|
| Vocal Cord Paralysis | 1 | 2011 | 82 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 3441 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 787 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Histones | 1 | 2017 | 1466 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2010 | 122 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 918 | 0.090 |
Why?
|
| Subclavian Artery | 1 | 2009 | 80 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 8873 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.090 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5159 | 0.080 |
Why?
|
| Prevalence | 3 | 2018 | 3260 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 328 | 0.080 |
Why?
|
| Age Distribution | 2 | 2007 | 698 | 0.080 |
Why?
|
| Abdominal Wall | 1 | 2011 | 184 | 0.080 |
Why?
|
| Texas | 3 | 2018 | 6311 | 0.080 |
Why?
|
| Sodium Pertechnetate Tc 99m | 2 | 2005 | 3 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2009 | 83 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 301 | 0.080 |
Why?
|
| Contraindications | 1 | 2008 | 150 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 3251 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2008 | 69 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 78 | 0.080 |
Why?
|
| North America | 2 | 2021 | 314 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 114 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 492 | 0.080 |
Why?
|
| Affect | 1 | 2009 | 288 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 529 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1350 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6100 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2010 | 598 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2003 | 732 | 0.080 |
Why?
|
| Catecholamines | 1 | 2007 | 101 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 249 | 0.070 |
Why?
|
| Ligaments | 1 | 2007 | 43 | 0.070 |
Why?
|
| Gamma Cameras | 2 | 2008 | 40 | 0.070 |
Why?
|
| Anesthesia, Intravenous | 1 | 2007 | 42 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 297 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2007 | 137 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2017 | 2669 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 359 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 1371 | 0.070 |
Why?
|
| Calcinosis | 1 | 2010 | 423 | 0.070 |
Why?
|
| Dissection | 1 | 2007 | 156 | 0.070 |
Why?
|
| Frozen Sections | 1 | 2006 | 105 | 0.070 |
Why?
|
| Heart Failure | 1 | 2000 | 2516 | 0.070 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2006 | 38 | 0.070 |
Why?
|
| Vacuum | 1 | 2006 | 42 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2011 | 636 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2006 | 107 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4849 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3518 | 0.070 |
Why?
|
| Posture | 1 | 2007 | 215 | 0.070 |
Why?
|
| Pedigree | 2 | 2017 | 1890 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 1171 | 0.070 |
Why?
|
| Organ Size | 1 | 2007 | 690 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 4757 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 313 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 208 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 402 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2010 | 665 | 0.070 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 108 | 0.070 |
Why?
|
| Mediastinum | 1 | 2007 | 268 | 0.070 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2004 | 10 | 0.060 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4078 | 0.060 |
Why?
|
| Depression | 2 | 2012 | 1715 | 0.060 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2004 | 61 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 202 | 0.060 |
Why?
|
| Choristoma | 1 | 2005 | 85 | 0.060 |
Why?
|
| Cysts | 1 | 2006 | 197 | 0.060 |
Why?
|
| Pyrroles | 1 | 2008 | 576 | 0.060 |
Why?
|
| Respiration | 1 | 2007 | 447 | 0.060 |
Why?
|
| Health Surveys | 1 | 2006 | 402 | 0.060 |
Why?
|
| Goiter | 1 | 2004 | 17 | 0.060 |
Why?
|
| Brain | 2 | 2009 | 4113 | 0.060 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 128 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15862 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 361 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2006 | 275 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2005 | 294 | 0.060 |
Why?
|
| Phenotype | 4 | 2017 | 6295 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 7789 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2003 | 115 | 0.060 |
Why?
|
| Rosaniline Dyes | 1 | 2003 | 108 | 0.060 |
Why?
|
| Indoles | 1 | 2008 | 1009 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 3639 | 0.050 |
Why?
|
| Cosmetics | 1 | 2002 | 17 | 0.050 |
Why?
|
| Genetic Counseling | 2 | 2018 | 380 | 0.050 |
Why?
|
| Minnesota | 1 | 2022 | 93 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2020 | 851 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 4988 | 0.050 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 6009 | 0.050 |
Why?
|
| Osteitis Fibrosa Cystica | 1 | 2001 | 2 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2009 | 3890 | 0.050 |
Why?
|
| Granuloma, Giant Cell | 1 | 2001 | 17 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 904 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 361 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 59536 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1323 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 4975 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 764 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 1987 | 0.050 |
Why?
|
| Wound Healing | 1 | 2006 | 815 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2004 | 549 | 0.050 |
Why?
|
| Bone Diseases | 1 | 2001 | 143 | 0.050 |
Why?
|
| Mammography | 2 | 2003 | 1010 | 0.050 |
Why?
|
| Carcinoma, Lobular | 1 | 2004 | 611 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2006 | 927 | 0.040 |
Why?
|
| Comorbidity | 1 | 2005 | 2352 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 694 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 196 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 187 | 0.040 |
Why?
|
| Pathology | 1 | 1999 | 101 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 2 | 2011 | 3976 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2010 | 155 | 0.040 |
Why?
|
| Smoking | 1 | 2008 | 2440 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2884 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 294 | 0.040 |
Why?
|
| Proteins | 1 | 2006 | 1963 | 0.040 |
Why?
|
| Data Collection | 1 | 1999 | 620 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1491 | 0.040 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.040 |
Why?
|
| Breast | 1 | 2003 | 1344 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 1216 | 0.040 |
Why?
|
| New South Wales | 1 | 2016 | 8 | 0.040 |
Why?
|
| Autografts | 1 | 2016 | 165 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 21 | 0.030 |
Why?
|
| Synaptophysin | 1 | 1995 | 79 | 0.030 |
Why?
|
| Chromogranins | 1 | 1995 | 84 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 165 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.030 |
Why?
|
| DNA Repair | 1 | 2003 | 1872 | 0.030 |
Why?
|
| Gene Expression | 1 | 2003 | 3570 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2011 | 690 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 2083 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 170 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 644 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1000 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 124 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.030 |
Why?
|
| Role | 1 | 2014 | 48 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6150 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 381 | 0.030 |
Why?
|
| Amylases | 1 | 1994 | 66 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 277 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 1328 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1994 | 80 | 0.030 |
Why?
|
| Religion | 1 | 2014 | 91 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3472 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 756 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2021 | 1423 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 554 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1084 | 0.030 |
Why?
|
| Decision Making | 1 | 1999 | 1287 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 884 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 68 | 0.020 |
Why?
|
| Chromaffin System | 1 | 2010 | 7 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.020 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2011 | 16 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2315 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2008 | 2316 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 177 | 0.020 |
Why?
|
| Metanephrine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Carney Complex | 1 | 2010 | 7 | 0.020 |
Why?
|
| Heart Rate | 1 | 2003 | 737 | 0.020 |
Why?
|
| Sepsis | 1 | 2015 | 652 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 71 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2017 | 1824 | 0.020 |
Why?
|
| Abdomen | 1 | 2011 | 332 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 339 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 3203 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 208 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1656 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 573 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2011 | 183 | 0.020 |
Why?
|
| Acute Disease | 1 | 1994 | 2422 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 106 | 0.020 |
Why?
|
| Dopamine | 1 | 2010 | 312 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 706 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 445 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 1183 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2008 | 176 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 761 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1994 | 610 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 479 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 462 | 0.020 |
Why?
|
| Liver | 2 | 2012 | 2961 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 2370 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 716 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2010 | 492 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.020 |
Why?
|
| Duodenoscopy | 1 | 2005 | 18 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1399 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 1904 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2012 | 1011 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 2004 | 20 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 937 | 0.020 |
Why?
|
| Somatostatin | 1 | 2005 | 114 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 1152 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2004 | 275 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 671 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 669 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2003 | 62 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2005 | 264 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 239 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2004 | 220 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 11965 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 492 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 726 | 0.010 |
Why?
|
| Alleles | 1 | 2008 | 2437 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 4917 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2005 | 889 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2005 | 620 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 1547 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 2022 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2005 | 1112 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 4821 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 3151 | 0.010 |
Why?
|